Recombinant IL2RA (Daclizumab Biosimilar) 抗体
This anti-IL2RA (Daclizumab Biosimilar) antibody is a 小鼠 单克隆 antibody detecting IL2RA (Daclizumab Biosimilar) in FACS 和 in vivo. Suitable for 人.
Quick Overview for Recombinant IL2RA (Daclizumab Biosimilar) 抗体 (ABIN7795104)
抗原
IL2RA (Daclizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
小鼠
克隆类型
单克隆
标记
This IL2RA (Daclizumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Daclizumab Biosimilar, CD25 Monoclonal Antibody
-
产品特性
- Daclizumab Biosimilar uses the same protein sequences as the therapeutic antibody daclizumab. Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90 % ) and murine (10 %) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human CD25
-
-
anti-IL2RA (Daclizumab Biosimilar) antibody
适用: 人, Cynomolgus, 猕猴 FACS, BR 宿主: 兔 Chimeric unconjugated Recombinant Antibody
anti-IL2RA (Daclizumab Biosimilar) antibody适用: 人, Cynomolgus, 猕猴 FACS, BR 宿主: Human Monoclonal unconjugated Recombinant Antibody
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- IL2RA (Daclizumab Biosimilar)
-
别名
- Daclizumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
